share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K:重大事件
美股SEC公告 ·  2024/08/21 05:05

Moomoo AI 已提取核心訊息

BioVie has successfully regained compliance with Nasdaq's minimum bid price requirement, as confirmed by Nasdaq Staff on August 20, 2024. The company's Class A common stock maintained a closing bid price above $1.00 per share for 10 consecutive business days from August 6 through August 19, 2024.This development resolves the compliance issue first reported on April 19, 2024, when BioVie received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) after its stock traded below $1.00 for 30 consecutive business days. The company has committed to maintaining adherence to Nasdaq's listing standards going forward.
BioVie has successfully regained compliance with Nasdaq's minimum bid price requirement, as confirmed by Nasdaq Staff on August 20, 2024. The company's Class A common stock maintained a closing bid price above $1.00 per share for 10 consecutive business days from August 6 through August 19, 2024.This development resolves the compliance issue first reported on April 19, 2024, when BioVie received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) after its stock traded below $1.00 for 30 consecutive business days. The company has committed to maintaining adherence to Nasdaq's listing standards going forward.
BioVie已成功恢復符合納斯達克最低買盤價格要求,這一消息由納斯達克員工在2024年8月20日確認。該公司的A類普通股在2024年8月6日至8月19日期間連續10個交易日的收盤買盤價格均高於每股1.00美元。這一進展解決了最初在2024年4月19日報告的合規問題,當時BioVie因其股票連續30個交易日交易價格低於1.00美元而收到關於不合規的通知,依據的是納斯達克上市規則5550(a)(2)。公司承諾將繼續遵守納斯達克的上市標準。
BioVie已成功恢復符合納斯達克最低買盤價格要求,這一消息由納斯達克員工在2024年8月20日確認。該公司的A類普通股在2024年8月6日至8月19日期間連續10個交易日的收盤買盤價格均高於每股1.00美元。這一進展解決了最初在2024年4月19日報告的合規問題,當時BioVie因其股票連續30個交易日交易價格低於1.00美元而收到關於不合規的通知,依據的是納斯達克上市規則5550(a)(2)。公司承諾將繼續遵守納斯達克的上市標準。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息